MindMed’s LSD Neutralizer Study Begins Feb 17 • 5 min read MindMed announced the start of a study for its LSD neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.
Mydecine Innovations Group Closes $17,250,000 Bought-Deal Public Offering Feb 15 • 3 min read Mydecine Innovations Group announced the closing of its previously-announced bought-deal public offering led by Canaccord Genuity Corp.
PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke Feb 12 • 4 min read PharmaDrug Inc. announced it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation for N,N-Dimethyltryptamine (“DMT”).
MindMed Signs Partnership with MindShift Compounds AG Feb 11 • 4 min read MindMed announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.
XPhyto Adds Mescaline Production to Psychedelic Medicine Programs Feb 10 • 3 min read XPhyto Therapeutics Corp. announced that XPhyto Laboratories Inc., its wholly owned Alberta subsidiary, has added mescaline production to its psychedelic medicine programs.